Study of Apatinib Combined With Oral Vinorelbine in Metastatic HER2 Negative Breast Cancer
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The hypothesis of this study is to discover if the all-oral therapy with apatinib plus oral
vinorelbine can shrink or slow the growth of pretreated HER2 negative metastatic breast
cancer.